epirubicin,cyclophosphamide,paclitaxel,carrelizumab
Showing 1 - 1 of 1
TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
- epirubicin,cyclophosphamide,paclitaxel
- (no location specified)
May 8, 2023